Avastin-Tarceva combo fails in lung cancer trial
October 6th, 2008
Genentech Inc. and OSI Pharmaceuticals Inc. said Monday a combination of two cancer drugs missed its primary goal in a clinical trial, failing to improve survival for patients with lung cancer.